Literature DB >> 18160013

Immunogenicity in macaques of the clinical product for a clade B DNA/MVA HIV vaccine: elicitation of IFN-gamma, IL-2, and TNF-alpha coproducing CD4 and CD8 T cells.

Harriet L Robinson1, Sunita Sharma, Jun Zhao, Sunil Kannanganat, Lilin Lai, Lakshmi Chennareddi, Tianwei Yu, David C Montefiori, Rama Rao Amara, Linda S Wyatt, Bernard Moss.   

Abstract

The clinical product for a clade B HIV DNA/MVA vaccine expressing Gag, Pol, and Env has been tested for immunogenicity in macaques. Responding T cells were at the threshold for detection following DNA priming at weeks 0 and 8 but underwent sharp expansions and contractions following MVA boosting at weeks 16 and 24. Both CD4 and CD8 T cell responses had high frequencies of cytokine coproducing cells with >50% of the memory cells coproducing multiple cytokines including IL-2. The highest responses were elicited to Gag, followed by Env and then Pol. In two of six macaques, the vaccine also elicited low levels of neutralizing Ab for easy to neutralize clade B isolates.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18160013     DOI: 10.1089/aid.2007.0165

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  19 in total

1.  Preexisting vaccinia virus immunity decreases SIV-specific cellular immunity but does not diminish humoral immunity and efficacy of a DNA/MVA vaccine.

Authors:  Sunil Kannanganat; Pragati Nigam; Vijayakumar Velu; Patricia L Earl; Lilin Lai; Lakshmi Chennareddi; Benton Lawson; Robert L Wilson; David C Montefiori; Pamela A Kozlowski; Bernard Moss; Harriet L Robinson; Rama Rao Amara
Journal:  J Immunol       Date:  2010-11-12       Impact factor: 5.422

2.  Comparative studies on in vitro expression and in vivo immunogenicity of supercoiled and open circular forms of plasmid DNA vaccines.

Authors:  Vinod Bhaskara Pillai; Michael Hellerstein; Tianwei Yu; Rama Rao Amara; Harriet L Robinson
Journal:  Vaccine       Date:  2007-10-30       Impact factor: 3.641

3.  Post-translational intracellular trafficking determines the type of immune response elicited by DNA vaccines expressing Gag antigen of Human Immunodeficiency Virus Type 1 (HIV-1).

Authors:  Aaron Wallace; Kim West; Alan L Rothman; Francis A Ennis; Shan Lu; Shixia Wang
Journal:  Hum Vaccin Immunother       Date:  2013-08-13       Impact factor: 3.452

4.  Efficacy of multivalent adenovirus-based vaccine against simian immunodeficiency virus challenge.

Authors:  Danilo R Casimiro; Kara Cox; Aimin Tang; Kara J Sykes; Meizhen Feng; Fubao Wang; Andrew Bett; William A Schleif; Xiaoping Liang; Jessica Flynn; Timothy W Tobery; Keith Wilson; Adam Finnefrock; Lingyi Huang; Salvatore Vitelli; Jing Lin; Deepa Patel; Mary-Ellen Davies; Gwendolyn J Heidecker; Daniel C Freed; Sheri Dubey; David H O'Connor; David I Watkins; Zhi-Qiang Zhang; John W Shiver
Journal:  J Virol       Date:  2009-12-30       Impact factor: 5.103

Review 5.  Immunogenicity and efficacy of DNA/MVA HIV vaccines in rhesus macaque models.

Authors:  Lynette Siv Chea; Rama Rao Amara
Journal:  Expert Rev Vaccines       Date:  2017-09-04       Impact factor: 5.217

6.  Immunogenic profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletions.

Authors:  Juan García-Arriaza; José Luis Nájera; Carmen E Gómez; Carlos Oscar S Sorzano; Mariano Esteban
Journal:  PLoS One       Date:  2010-08-24       Impact factor: 3.240

7.  Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials.

Authors:  Scott A Brown; Sherri L Surman; Robert Sealy; Bart G Jones; Karen S Slobod; Kristen Branum; Timothy D Lockey; Nanna Howlett; Pamela Freiden; Patricia Flynn; Julia L Hurwitz
Journal:  Viruses       Date:  2010-02-01       Impact factor: 5.048

8.  Virus-Like Particles Displaying Trimeric Simian Immunodeficiency Virus (SIV) Envelope gp160 Enhance the Breadth of DNA/Modified Vaccinia Virus Ankara SIV Vaccine-Induced Antibody Responses in Rhesus Macaques.

Authors:  Smita S Iyer; Sailaja Gangadhara; Blandine Victor; Xiaoying Shen; Xuemin Chen; Rafiq Nabi; Sudhir P Kasturi; Michael J Sabula; Celia C Labranche; Pradeep B J Reddy; Georgia D Tomaras; David C Montefiori; Bernard Moss; Paul Spearman; Bali Pulendran; Pamela A Kozlowski; Rama Rao Amara
Journal:  J Virol       Date:  2016-09-12       Impact factor: 5.103

9.  Adjuvantive effects of anti-4-1BB agonist Ab and 4-1BBL DNA for a HIV-1 Gag DNA vaccine: different effects on cellular and humoral immunity.

Authors:  Sumita Ganguly; Jinyan Liu; Vinod B Pillai; Robert S Mittler; Rama Rao Amara
Journal:  Vaccine       Date:  2009-11-26       Impact factor: 3.641

10.  Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity.

Authors:  Lindvi Gudmundsdotter; Charlotta Nilsson; Andreas Brave; Bo Hejdeman; Patricia Earl; Bernard Moss; Merlin Robb; Josephine Cox; Nelson Michael; Mary Marovich; Gunnel Biberfeld; Eric Sandström; Britta Wahren
Journal:  Vaccine       Date:  2009-05-29       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.